Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710237 | 1.00 | MAPT (0.47) | MAPTDDB1CRBNNR1H2GPR119 | |
| SCHEMBL30805657 | 0.88 | MAPT (0.58) | MAPTDDB1CRBNNR1H2GPR119 | |
| SCHEMBL1620629 | 0.88 | MAPT (0.58) | MAPTDDB1CRBNNR1H2GPR119 | |
| SCHEMBL11929920 | 0.88 | ESR2 (0.51) | MAPTDDB1CRBNNR1H2GPR119 | |
| SCHEMBL7669805 | 0.87 | MAPT (0.57) | MAPTDDB1CRBNNR1H2GPR119 | |
| SCHEMBL7669808 | 0.87 | MAPT (0.57) | MAPTDDB1CRBNNR1H2GPR119 | |
| SCHEMBL14959492 | 0.84 | HDAC1 (0.48) | MAPTDDB1CRBNNAMPTHDAC1 | |
| SCHEMBL28419943 | 0.83 | NAMPT (0.44) | MAPTDDB1CRBNNR1H2NAMPT | |
| SCHEMBL11934332 | 0.81 | NAMPT (0.44) | MAPTMAPK1NAMPTHDAC1ABHD6 | |
| SCHEMBL23309152 | 0.81 | RIPK1 (0.45) | NAMPTHDAC1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115244048-A | Pyridopyrimidine derivatives useful for modulating AhR signaling | 捷豹治疗有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-113939295-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113727758-A | Bicyclic heterocyclic compounds and use thereof | 锐新医药公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| WO-2007133865-A2 | HCV/HIV INHIBITORS AN THEIR USES | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MAPT 1444/4885DDB1 1547/4885CRBN 1979/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | MAPT 4041/4885DDB1 1326/4885CRBN 1764/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | MAPT 1378/4885DDB1 2777/4885CRBN 2158/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | MAPT 1444/4885DDB1 1547/4885CRBN 1979/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MAPT 1444/4885DDB1 1547/4885CRBN 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.